SLC7A11 and hepatocellular carcinoma: For instance, a sorafenib-loaded Fe-MOF nanoplatform (Sor@Fe-MOF) in an HCC model not only enhanced ferroptosis by releasing iron ions and sorafenib to downregulate GPX4 and SLC7A11 expression synergistically but also effectively remodeled the tumor immune microenvironment to activate anti-tumor immunity [158].